ALFA Finder| Value | ₹580.0 Cr |
|---|
BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,827.50
- Market cap
- ₹1,06,141 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.2×Sector 43.8×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Business Update
Aurobindo Pharma disclosed that US FDA classified its Lannett facility inspection as Official Action Indicated (OAI). The company states there is no quantifiable financial or operational impact.
Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Other debt & borrowing announcements
All →HDFC Life Insurance Company Debt & Borrowing
HDFC Life intimated a CRC meeting on November 16, 2026, to approve commercial terms for up to ₹500 Crore of unsecured subordinated NCDs. The filing only schedules the meeting; no terms are yet approved.
Repco Home Finance Debt & Borrowing
Repco Home Finance submitted a revised Security Cover and Covenant Compliance Certificate as of 30 September 2026, extending compliance coverage to all Debenture Trust Deed covenants. The revision follows the earlier certificate and only changes the covenant scope and UDIN.
Triveni Turbine Debt & Borrowing: ₹56.21 Cr
Triveni Turbine enhanced its corporate guarantee for subsidiary TTAPL by USD 6 million. Guarantee amount is Rs.56.21 Crore, lifting the facility limit to USD 15 million.
- Value
- ₹56.21 Cr
TSF Investments Debt & Borrowing
TSF Investments' board approved up to ₹1,500 Crore in debt instruments of group companies. The material related-party deal needs shareholder approval via postal ballot.
Motilal Oswal Financial Services Debt & Borrowing: ₹150 Cr
Motilal Oswal Financial Services certified timely payment of the Rs.150 Crore maturity on commercial paper ISIN INE338I14NE7, due 11 November 2026. This confirms fulfilment of a debt obligation.
- Value
- ₹150.0 Cr
Glottis Debt & Borrowing: ₹60 Cr
Glottis's board approved up to ₹60 Crore of interest-free unsecured loans from two Managing Directors. The related-party loans fund working capital and are not at arm's length.
- Value
- ₹60.00 Cr
- Execution
- Up to 5 years from each tranche disbursement